Hill-Rom Holdings Inc (NYSE:HRC) had its price objective raised by Barclays PLC from $86.00 to $90.00 in a research note issued to investors on Monday morning. They currently have an overweight rating on the medical technology company’s stock.

Several other equities research analysts have also issued reports on HRC. ValuEngine lowered Hill-Rom Holdings from a buy rating to a hold rating in a research report on Saturday, November 4th. Stifel Nicolaus increased their price target on Hill-Rom Holdings from $84.00 to $85.00 and gave the stock a buy rating in a research note on Monday. Zacks Investment Research raised Hill-Rom Holdings from a sell rating to a hold rating in a research note on Tuesday, October 3rd. Needham & Company LLC decreased their price target on Hill-Rom Holdings from $95.00 to $93.00 and set a buy rating for the company in a research note on Friday, July 28th. Finally, BidaskClub raised Hill-Rom Holdings from a sell rating to a hold rating in a research note on Sunday, August 6th. Four equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The stock currently has an average rating of Buy and a consensus price target of $88.57.

Shares of Hill-Rom Holdings (NYSE:HRC) traded down $0.59 during trading hours on Monday, hitting $77.60. The stock had a trading volume of 115,856 shares, compared to its average volume of 510,497. The stock has a market cap of $5,169.66, a PE ratio of 20.33, a P/E/G ratio of 1.67 and a beta of 1.19. Hill-Rom Holdings has a 1-year low of $50.50 and a 1-year high of $84.65. The company has a quick ratio of 1.34, a current ratio of 1.77 and a debt-to-equity ratio of 1.55.

Hill-Rom Holdings (NYSE:HRC) last released its quarterly earnings results on Friday, November 3rd. The medical technology company reported $1.32 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.27 by $0.05. The firm had revenue of $738.30 million during the quarter, compared to analysts’ expectations of $731.10 million. Hill-Rom Holdings had a return on equity of 20.27% and a net margin of 4.87%. Hill-Rom Holdings’s quarterly revenue was up 4.6% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.18 EPS. research analysts expect that Hill-Rom Holdings will post 4.26 EPS for the current year.

COPYRIGHT VIOLATION NOTICE: This piece was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece on another website, it was stolen and reposted in violation of international copyright & trademark legislation. The correct version of this piece can be read at https://www.thecerbatgem.com/2017/11/09/barclays-plc-raises-hill-rom-holdings-inc-hrc-price-target-to-90-00.html.

The company also recently announced a quarterly dividend, which will be paid on Friday, December 29th. Investors of record on Friday, December 15th will be paid a dividend of $0.18 per share. The ex-dividend date is Thursday, December 14th. This represents a $0.72 annualized dividend and a yield of 0.93%. Hill-Rom Holdings’s dividend payout ratio is currently 36.18%.

In related news, SVP Andreas G. Frank sold 6,870 shares of the stock in a transaction on Thursday, September 14th. The stock was sold at an average price of $77.48, for a total value of $532,287.60. Following the completion of the transaction, the senior vice president now owns 16,701 shares in the company, valued at approximately $1,293,993.48. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Andreas G. Frank sold 3,940 shares of the stock in a transaction on Wednesday, September 13th. The shares were sold at an average price of $77.84, for a total value of $306,689.60. Following the completion of the transaction, the senior vice president now owns 16,701 shares of the company’s stock, valued at approximately $1,300,005.84. The disclosure for this sale can be found here. Company insiders own 2.20% of the company’s stock.

Several large investors have recently added to or reduced their stakes in the stock. American International Group Inc. boosted its position in shares of Hill-Rom Holdings by 9.9% in the 3rd quarter. American International Group Inc. now owns 134,779 shares of the medical technology company’s stock valued at $9,974,000 after purchasing an additional 12,114 shares during the period. Sivik Global Healthcare LLC boosted its position in shares of Hill-Rom Holdings by 25.0% in the 3rd quarter. Sivik Global Healthcare LLC now owns 50,000 shares of the medical technology company’s stock valued at $3,700,000 after purchasing an additional 10,000 shares during the period. Olstein Capital Management L.P. boosted its position in shares of Hill-Rom Holdings by 22.9% in the 3rd quarter. Olstein Capital Management L.P. now owns 88,780 shares of the medical technology company’s stock valued at $6,570,000 after purchasing an additional 16,540 shares during the period. ING Groep NV boosted its position in shares of Hill-Rom Holdings by 10.8% in the 3rd quarter. ING Groep NV now owns 8,069 shares of the medical technology company’s stock valued at $597,000 after purchasing an additional 788 shares during the period. Finally, Icon Advisers Inc. Co. acquired a new position in shares of Hill-Rom Holdings in the 3rd quarter valued at $429,000. Institutional investors and hedge funds own 81.92% of the company’s stock.

About Hill-Rom Holdings

Hill-Rom Holdings, Inc is a global medical technology company. The Company operates through four segments: North America Patient Support Systems, International Patient Support Systems, Front Line Care and Surgical Solutions. The Company’s products and services include Patient Support Systems, Front Line Care and Surgical Solutions.

Analyst Recommendations for Hill-Rom Holdings (NYSE:HRC)

Receive News & Stock Ratings for Hill-Rom Holdings Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hill-Rom Holdings Inc and related stocks with our FREE daily email newsletter.